BACKGROUND: This study aimed to evaluate stereotactic body radiation therapy (SBRT) in @entity1 with stage I @entity1149 ( @entity1149 ) in terms of radiation-induced changes and computed tomography (CT) features of local recurrence by @entity419 positron emission tomography ( @entity419 -PET). METHODS: From January 2006 to December 2012, 81 @entity1 with @entity1149 received SBRT. Follow-up consisted of non-contrast enhanced CT scans performed before and every four months after SBRT. In addition, @entity419 -PET/CT was conducted before SBRT for each @entity1 , and one year later for each case suspected of recurrence. The CT findings were classified into two categories: mass-like @entity82 and others. The mass-like @entity82 category was subdivided into two patterns: mass-like consolidation (with air bronchogram) and mass-like @entity231 . RESULTS: Six @entity1 had histologically confirmed local recurrence, including 83% (5/6) with mass-like @entity231 pattern and one case of modified conventional pattern (P = 0.02). In contrast, the non-recurrent group exhibited only 7% (5/75) with mass-like @entity231 and 13% (10/75) with mass-like consolidation pattern. Five @entity1 with local recurrence presented with the mass-like @entity231 pattern, compared with 33% of @entity1 (5/15) from the non-recurrent group (P = 0.01) and showed an increase in maximum diameter at >= 12 months after SBRT. The recurrent group also had a significantly higher standardized uptake value (SUVmax) than the non-recurrent group (P < 0.001), with all values >5 (range: 5.7-25.4). CONCLUSION: The following characteristics of mass-like @entity82 should be considered indicators of local recurrence after SBRT: @entity231 pattern, increasing maximum diameter, and SUVmax > 5.

Imaging characteristics of local recurrences after stereotactic body radiation therapy for stage I @entity1149 : Evaluation of mass-like XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis'] @entity419 :: ('MESH:D019788', 'Chemical') :: ['18F-fluorodeoxyglucose', '(18)F-FDG', '18F-FDG'] @entity231 :: ('MESH:D002386', 'Disease') :: ['opacity'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']
@entity82 :: (MESH:D005355,Disease) :: ['fibrosis']
